An intricate interaction network was observed for five of these targets (CD59, FCRL3, CR1, TNFRSF1A, and TYMP) with 19 known targets of 10 existing MS drugs including ublituximab, ofatumumab, ocrelizumab, glatiramer, alemtuzumab, natalizumab, cladribine, interferon beta, dimethyl fumarate, and teriflunomide, as well as the previous MS drug daclizumab, which is not licensed due to severe liver toxicity (Fig. 4 and SI Appendix, Table S14). Here, FCRL3 is linked to myeloid sarcoma.